Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.35 |
| ▸ | CA2 | P00918 | 5/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA3 | P07451 | 3/20 | 0.34 |
| ▸ | CA4 | P22748 | 3/20 | 0.34 |
| ▸ | CA6 | P23280 | 3/20 | 0.34 |
| ▸ | CA5A | P35218 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948181 | 0.88 | TRPV4 (0.46) | TRPV4POLBAPEX1CA1CA2 | |
| SCHEMBL3912870 | 0.88 | TRPV4 (0.46) | TRPV4CA1CA2CA9PTGES2 | |
| SCHEMBL26978287 | 0.86 | TRPV4 (0.44) | TRPV4POLBAPEX1CA1CA2 | |
| SCHEMBL1501202 | 0.84 | TRPV4 (0.41) | TRPV4POLBAPEX1CA1CA2 | |
| SCHEMBL30485974 | 0.84 | TRPV4 (0.41) | TRPV4POLBAPEX1CA1CA2 | |
| SCHEMBL17017265 | 0.83 | TRPV4 (0.42) | TRPV4POLBAPEX1CA1CA2 | |
| SCHEMBL31462898 | 0.83 | TRPV4 (0.42) | TRPV4POLBAPEX1CA1CA2 | |
| SCHEMBL3948765 | 0.83 | TRPV4 (0.42) | TRPV4CA1CA2CA9PTGES2 | |
| SCHEMBL31462899 | 0.83 | TRPV4 (0.42) | TRPV4POLBAPEX1CA1CA2 | |
| SCHEMBL1991714 | 0.82 | TRPV4 (0.50) | TRPV4POLBAPEX1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3144300-B1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | DAIICHI SANKYO CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9845313-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-19 | — | — | US | disclosed |
| EP-2758399-B1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-11-15 | — | — | EP | disclosed |
| EP-3144300-A1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | Daiichi Sankyo Company, Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9493448-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| EP-2813491-B1 | CYCLOALKANE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-9174993-B2 | N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2015-11-03 | — | — | US | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-20140357640-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-04 | — | — | US | disclosed |
| WO-2009017719-A2 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1992623-A1 | Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes | Astra Zeneca AB (SE) | 2008-11-19 | — | — | EP | disclosed |
| EP-1888544-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| EP-1797065-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006066109-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006029210-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | TRPV4 892/4885POLB 3771/4885APEX1 4715/4885 |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | TRPV4 1/4885POLB 4849/4885APEX1 4240/4885 |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | TRPV1, TRPA1, SCNN1A | TRPV4 23/4885POLB 3201/4885APEX1 2830/4885 |
| US-20140357640-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK3, SGK1, SGK2 | TRPV4 1001/4885POLB 4508/4885APEX1 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.